FLT4

FLT4
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
Aliases FLT4, FLT41, LMPH1A, PCL, VEGFR3, FLT-4, VEGFR-3, fms related tyrosine kinase 4
External IDs MGI: 95561 HomoloGene: 7321 GeneCards: FLT4
Targeted by Drug
cediranib, lenvatinib, linifanib, motesanib, nintedanib, pazopanib, sunitinib, tivozanib, vatalanib[1]
Orthologs
Species Human Mouse
Entrez

2324

14257

Ensembl

ENSG00000037280

ENSMUSG00000020357

UniProt

P35916

P35917

RefSeq (mRNA)

NM_002020
NM_182925

NM_008029

RefSeq (protein)

NP_002011.2
NP_891555.2

NP_032055.1

Location (UCSC) Chr 5: 180.6 – 180.65 Mb Chr 11: 49.61 – 49.65 Mb
PubMed search [2] [3]
Wikidata
View/Edit HumanView/Edit Mouse

Fms-related tyrosine kinase 4, also known as FLT4, is a protein which in humans is encoded by the FLT4 gene.[4][5]

This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA.[4]

Interactions

FLT4 has been shown to interact with SHC1.[6][7][8]

See also

References

  1. ↑ "Drugs that physically interact with Vascular endothelial growth factor receptor 3 view/edit references on wikidata".
  2. ↑ "Human PubMed Reference:".
  3. ↑ "Mouse PubMed Reference:".
  4. 1 2 "Entrez Gene: FLT4 fms-related tyrosine kinase 4".
  5. ↑ Galland F, Karamysheva A, Mattei MG, Rosnet O, Marchetto S, Birnbaum D (June 1992). "Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene". Genomics. 13 (2): 475–8. doi:10.1016/0888-7543(92)90277-Y. PMID 1319394.
  6. ↑ Pajusola K, Aprelikova O, Pelicci G, Weich H, Claesson-Welsh L, Alitalo K (December 1994). "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors". Oncogene. 9 (12): 3545–55. PMID 7970715.
  7. ↑ Fournier E, Blaikie P, Rosnet O, Margolis B, Birnbaum D, Borg JP (January 1999). "Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling". Oncogene. 18 (2): 507–14. doi:10.1038/sj.onc.1202315. PMID 9927207.
  8. ↑ Fournier E, Rosnet O, Marchetto S, Turck CW, Rottapel R, Pelicci PG, Birnbaum D, Borg JP (May 1996). "Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase". The Journal of Biological Chemistry. 271 (22): 12956–63. doi:10.1074/jbc.271.22.12956. PMID 8662748.

Further reading

  • Petrova TV, Makinen T, Alitalo K (November 1999). "Signaling via vascular endothelial growth factor receptors". Experimental Cell Research. 253 (1): 117–30. doi:10.1006/excr.1999.4707. PMID 10579917. 
  • Aprelikova O, Pajusola K, Partanen J, Armstrong E, Alitalo R, Bailey SK, McMahon J, Wasmuth J, Huebner K, Alitalo K (February 1992). "FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter". Cancer Research. 52 (3): 746–8. PMID 1310071. 
  • Galland F, Karamysheva A, Mattei MG, Rosnet O, Marchetto S, Birnbaum D (June 1992). "Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene". Genomics. 13 (2): 475–8. doi:10.1016/0888-7543(92)90277-Y. PMID 1319394. 
  • Pajusola K, Aprelikova O, Korhonen J, Kaipainen A, Pertovaara L, Alitalo R, Alitalo K (October 1992). "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines". Cancer Research. 52 (20): 5738–43. PMID 1327515. 
  • Fournier E, Dubreuil P, Birnbaum D, Borg JP (September 1995). "Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor". Oncogene. 11 (5): 921–31. PMID 7675451. 
  • Pajusola K, Aprelikova O, Armstrong E, Morris S, Alitalo K (November 1993). "Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts". Oncogene. 8 (11): 2931–7. PMID 7692369. 
  • Pajusola K, Aprelikova O, Pelicci G, Weich H, Claesson-Welsh L, Alitalo K (December 1994). "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors". Oncogene. 9 (12): 3545–55. PMID 7970715. 
  • Galland F, Karamysheva A, Pebusque MJ, Borg JP, Rottapel R, Dubreuil P, Rosnet O, Birnbaum D (May 1993). "The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor". Oncogene. 8 (5): 1233–40. PMID 8386825. 
  • Fournier E, Rosnet O, Marchetto S, Turck CW, Rottapel R, Pelicci PG, Birnbaum D, Borg JP (May 1996). "Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase". The Journal of Biological Chemistry. 271 (22): 12956–63. doi:10.1074/jbc.271.22.12956. PMID 8662748. 
  • Lee J, Gray A, Yuan J, Luoh SM, Avraham H, Wood WI (March 1996). "Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4". Proceedings of the National Academy of Sciences of the United States of America. 93 (5): 1988–92. doi:10.1073/pnas.93.5.1988. PMC 39896Freely accessible. PMID 8700872. 
  • Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K (December 1996). "VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development". Development. 122 (12): 3829–37. PMID 9012504. 
  • Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA (January 1998). "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)". Proceedings of the National Academy of Sciences of the United States of America. 95 (2): 548–53. doi:10.1073/pnas.95.2.548. PMC 18457Freely accessible. PMID 9435229. 
  • Ferrell RE, Levinson KL, Esman JH, Kimak MA, Lawrence EC, Barmada MM, Finegold DN (December 1998). "Hereditary lymphedema: evidence for linkage and genetic heterogeneity". Human Molecular Genetics. 7 (13): 2073–8. doi:10.1093/hmg/7.13.2073. PMID 9817924. 
  • Fournier E, Blaikie P, Rosnet O, Margolis B, Birnbaum D, Borg JP (January 1999). "Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling". Oncogene. 18 (2): 507–14. doi:10.1038/sj.onc.1202315. PMID 9927207. 
  • Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN (June 2000). "Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema". Nature Genetics. 25 (2): 153–9. doi:10.1038/75997. PMID 10835628. 
  • Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M (August 2000). "Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase". American Journal of Human Genetics. 67 (2): 295–301. doi:10.1086/303019. PMC 1287178Freely accessible. PMID 10856194. 
  • Wang JF, Zhang XF, Groopman JE (November 2001). "Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration". The Journal of Biological Chemistry. 276 (45): 41950–7. doi:10.1074/jbc.M101370200. PMID 11553610. 
  • Baldwin ME, Roufail S, Halford MM, Alitalo K, Stacker SA, Achen MG (November 2001). "Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis". The Journal of Biological Chemistry. 276 (47): 44307–14. doi:10.1074/jbc.M106188200. PMID 11574540. 
  • Walter JW, North PE, Waner M, Mizeracki A, Blei F, Walker JW, Reinisch JF, Marchuk DA (March 2002). "Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma". Genes, Chromosomes & Cancer. 33 (3): 295–303. doi:10.1002/gcc.10028. PMID 11807987. 

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This article is issued from Wikipedia - version of the 9/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.